collagen type V alpha 1 chainGenealiases: EDSC · EDSCL1 · FMDMF
Q-omics provides the consensus-scored COL5A1 profile across patient tissues and cancer cell-line models. COL5A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, COL5A1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, COL5A1 protein abundance shows 32,821 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, HNSC, and PDAC as cancer lineages where COL5A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL5A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL5A1 survival associations across molecular data types. COL5A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL5A1 RNA expression–survival associations across cancer types. High COL5A1 expression shows unfavorable associations in KIRP, MESO, ACC, BLCA, UVM and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for COL5A1 RNA expression.
This table summarizes COL5A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for COL5A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL5A1 shows higher tumor expression in HNSC, KIRC, COAD, LUAD, LUSC and STAD. The HNSC box plot shows higher COL5A1 RNA expression in tumor versus normal tissue (log2 FC = +5.433, t-test p < 0.001).
This table shows molecular features associated with COL5A1 in patient tissues and cancer cell lines. In patient samples, COL5A1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, COL5A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and CNS.
